The Patent Finder

NLS-1 Pharma AG

Also on record
Records under this name other than patents NLS-1 Pharma AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 6 of 6 · Back to NLS-1 Pharma AG

PatentTitleStatus Expires Confidence
US 8,293,779Mazindol Combination in the Treatment of Attention Deficit/Hyperactivity
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,207,271Mazindol IR/SR multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (ADHD)
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,596,622Mazindol Treatment for Heroin Dependence and Substance Use Disorder
Formerly held
In force
 · High confidence
In forceHigh confidence
US 9,637,447Lauflumide and the Enantiomers Thereof, Method for Preparing Same and Therapeutic Uses Thereof
Formerly held
Lapsed on the fee record
Ended May 2, 2025 · High confidence
Lapsed on the fee recordEnded May 2, 2025High confidence
US 10,532,100Use of iron for treating attention deficit hyperactivity disorder in children
Formerly held
Lapsed on the fee record
Ended Jan 14, 2024 · High confidence
Lapsed on the fee recordEnded Jan 14, 2024High confidence
US 10,456,387Phacetoperane for treating of attention deficit hyperactivity disorder
Formerly held
Lapsed on the fee record
Ended Oct 29, 2023 · From the USPTO record
Lapsed on the fee recordEnded Oct 29, 2023From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited